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Abstract
Purpose—Genomic alterations in blood-derived circulating tumor DNA (ctDNA) from patients 
with colorectal cancers were correlated with clinical outcomes.
Patients and Methods—Next-generation sequencing of ctDNA (54- to 73-gene panel) was 
performed in 94 patients with colorectal cancer.
Results—Most patients (96%) had metastatic or recurrent disease at the time of blood draw. The 
median number of nonsynonymous alterations per patient was three (range, zero to 30). The most 
frequently aberrant genes were TP53 (52.1% of patients), KRAS (34%), and APC (28.7%). 
Concordance between tissue and blood next-generation sequencing ranged from 63.2% (APC) to 
85.5% (BRAF). Altogether, 74 patients (79%) had one or more nonsynonymous alterations, 69 
(73%) had one or more potentially actionable alterations, and 61 (65%) had an alteration 
actionable by a drug approved by the US Food and Drug Administration (on or off label). Lung 
metastases correlated with improved survival from diagnosis in univariable analysis. ctDNA of 5% 
or more from blood tests as well as EGFR and ERBB2 (HER2) nonsynonymous alterations 
correlated with worse survival (but only ERBB2 remained significant in multivariable analysis). 
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No two patients had identical molecular portfolios. Overall, 65% versus 31% of patients treated 
with matched (n = 17) versus unmatched therapy (n = 18) after ctDNA testing achieved stable 
disease for 6 months or more, partial response, or complete response (P = .045); progression-free 
survival, 6.1 versus 2.3 months (P = .08); and survival not reached versus 9.4 months (P = .146; all 
by multivariable analysis).
Conclusion—Patients with colorectal cancer have heterogeneous ctDNA profiles, and most 
harbor potentially actionable ctDNA alterations. Matched therapy yielded higher rates of stable 
disease for 6 months or more, partial response, or complete response. ctDNA assessment may have 
clinical utility and merits further investigation.
INTRODUCTION
Colorectal cancer is one of the most common cancers worldwide. Globally, there were 1.4 
million new cases and 693,900 deaths in 2012, with an increase in incidence and mortality 
rates in developing countries.1,2 At diagnosis, approximately 20% of patients have distant 
metastatic disease.3 For decades, systemic therapy used fluorouracil as the main active 
agent. Addition of irinotecan and oxaliplatin, as well as the recently developed inhibitors 
that target VEGF (bevacizumab, aflibercept, and regorafenib) and EGFR (cetuximab and 
panitumumab), have markedly improved the outcome of patients with metastatic colorectal 
cancer. However, prognosis remains poor (median progression-free survival [PFS], 10 
months; median overall survival [OS], 19 to 28 months; 5-year survival, 10%4,5). Thus there 
is an unmet need to better understand the clinically relevant biology of colorectal cancer.
The molecular characteristics of colorectal cancer are better understood because of advances 
in next-generation sequencing (NGS) technology.6 Categorizing patients on the basis of their 
underlying molecular features has been proposed (ie, consensus molecular subtypes),7 and 
several genomic markers are now routinely used in the clinic to guide treatment. Examples 
of genomically guided US Food and Drug Administration (FDA)–approved therapies 
include anti-EGFR agents (cetuximab and panitumumab) among patients with wild-type 
RAS8–10 and pembrolizumab (anti-programmed cell death protein 1 antibody) for 
microsatellite instability-high or mismatch repair-deficient colorectal cancer.11 In additon, 
adding vemurafenib (BRAF inhibitor) to irinotecan and cetuximab demonstrated better 
clinical outcome among patients with 5RAfV600–mutated colorectal cancer.12 However, 
despite the recent progress in targeted therapy approaches, more than 50% of patients do not 
respond to the aforementioned regimens, and an increased understanding of the molecular 
underpinnings of the disease is needed. Some of the challenges with tissue-based genomic 
analyses, which often are performed on archival samples, include the fact that the genomic 
landscape of cancer can change after therapeutic intervention,13 and the sequencing results 
can be confounded by intra- and intertumoral hetero-geneity.14,15
To overcome the challenges of tumor heterogeneity and assess the impact of the clonal 
evolution that occurs with time and under therapeutic pressure, circulating tumor DNA 
(ctDNA) is now being actively investigated in diverse cancers.16–20 Previous studies using 
ctDNA analysis of colorectal cancer revealed that TP53, KRAS, and APC were the most 
commonly altered genes.21,22 Here, we provide an in-depth evaluation with clinical 
Kato et al. Page 2
JCO Precis Oncol. Author manuscript; available in PMC 2019 April 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
characteristics and therapeutic outcomes of patients with colorectal cancer whose ctDNA 
was interrogated by clinical-grade NGS.
PATIENTS AND METHODS
Patients
We reviewed the clinicopathologic and outcome data from 94 consecutively tested patients 
with advanced-stage colorectal cancer at the University of California San Diego Moores 
Cancer Center; each patient had the ctDNA test performed on their plasma (January 2015 to 
March 2017). The study followed the guidelines of the University of California, San Diego, 
Internal Review Board, the Declaration of Helsinki for the PREDICT study (NCT02478931; 
Profile Related Evidence Determining Individualized Cancer Therapy), and any 
investigational therapy for which the patients gave consent.
Sequencing, Concordance Rate, Matched Therapy, and Actionability
ctDNA sequencing was performed by Guardant Health and has been previously described 
(Data Supplement).16,23,24 Overall, 76 (81%) of 94 patients had NGS performed on tumor 
tissue using the FoundationOne assay. The methods have been previously described (Data 
Supplement).25 Tissue NGS and plasma ctDNA tests were compared by using the kappa 
statistic (Data Supplement).26 We retrospectively analyzed the treatments given after ctDNA 
testing and compared the clinical outcomes among patients who received matched and 
unmatched therapies (Data Supplement).27
Statistical Analysis
Statistical analysis was performed by M.C.S. with SPSS version 24.0 (SPSS, Chicago, IL; 
Data Supplement).28 The rate of stable disease (SD) for 6 months or more, partial response 
(PR), or complete response (CR) was compared between patients who received matched or 
unmatched therapy. SD, PR, and CR were determined according to an assessment by the 
treating physician. PFS was defined as the time from the beginning of therapy to progression 
or last follow-up date for patients who did not progress. OS was defined as the time from 
diagnosis until death or last follow-up date for patients still alive. PFS and OS were analyzed 
by using the Kaplan-Meier method28 and the log-rank test (univariable analysis); a Cox 
regression model (multivariable analysis) was used to compare variables. Patients still 
progression free (for PFS) or alive (for OS) at last follow-up were censored on that date.
RESULTS
Patient Characteristics
We evaluated 94 patients with colorectal cancer who had NGS of ctDNA. Median age at 
diagnosis was 50 years (range, 25 to 84 years). The majority of patients had metastasis or 
recurrence when blood was drawn for ctDNA testing (n = 90 [96%]) and had one or more 
nonsynonymous alterations (n = 74 [79%]; Table 1; Data Supplement).
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ctDNA Sequencing Results
The median time from diagnosis to ctDNA analysis was 19.2 months (95% CI, 15.6 to 29.2 
months). The median number of nonsynonymous alterations per patient was three (range, 
zero to 30). The most frequent nonsynonymous alterations were in TP53 (52.1%), KRAS 
(34%), APC (28.7%), BRAF (19.1%), PIK3CA (17%), and EGFR (16%) genes (Fig 1A). 
Location of the primary colorectal cancer (right or left side) did not influence the frequency 
of these alterations.
Distinctiveness of genomic portfolios.—Among the 74 patients with one or more 
nonsynonymous ctDNA alterations, 59 (79.7%) had distinct gene alteration portfolios; 15 
patients (20.3%) had similar genomic alteration portfolios (when alterations were considered 
at the gene level only, irrespective of the specific variant). This was the case only when 
patients had a small number of alterations (three or fewer) and included mostly the three 
genes with the most frequent alterations: TP53, KRAS, and APC (Fig 1B). Of note, all 15 
patients had distinct genomic alterations when gene variants were considered. Thus, no two 
patients had identical molecular profiles (considering both genes and their loci). Among the 
74 patients with one or more detectable non-synonymous ctDNA alterations, 93.2% (69 of 
74 patients) had one or more characterized anomalies that were potentially actionable by 
FDA-approved drugs (82.4%) or by experimental drugs (10.8%) in a clinical trial if an FDA-
approved drug was not available (Fig 1C-D).
Comparison of ctDNA and tissue NGS testing.—Overall, 76 patients (80.6%) had 
tissue NGS (Foundation Medicine; see Patients and Methods). The median time interval 
between the tissue biopsy and ctDNA testing was 5.8 months (range, 0.03 to 81 months; 
95% CI, 3.2 to 8.3 months). We found statistically significant correlations between driver 
alterations detected in ctDNA (TP53, KRAS, APC, and BRAF) when compared with those 
detected in tissue, with concordance rates ranging from 63.2% to 85.5%, depending on the 
genes (Appendix Fig A1; Data Supplement). We did not observe a difference in the 
concordance rate when the time interval between the blood draw and tissue biopsy were 
taken into consideration (a cutoff of 6 months was used because it was the median time 
interval). Although APC alterations seemed to be detected more frequently in the tissue than 
in the plasma (22 patients were positive in both tests, 27 patients were positive in tissue only, 
and one patient was positive in plasma only), BRAF alterations seemed to be detected more 
frequently in the ctDNA test (eight patients were positive in both tests, two were positive in 
tissue only, and nine were positive in plasma only). Of note, there was 100% concordance 
between ctDNA and tissue DNA testing specifically for BRAFV600E mutation (n = 6). In 
contrast, BRAF amplification was seen only with ctDNA testing (n = 8).
OS Analysis
First, we analyzed the impact of several clinical variables on OS calculated from the time of 
diagnosis (Table 2). In univariable analysis, the presence of nonsynonymous alterations in 
APC, BRAF, EGFR, MYC, and ERBB2 genes from ctDNA and the presence of one or more 
gene alterations with ctDNA of 5% or more correlated with a poorer survival (all P < .05). 
Of interest, patients with metastases localized in their lungs had a statistically significantly 
improved survival in univariable analysis. After the multivariable analysis, patients in whom 
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an alteration was detected with ctDNA of 5% or more still had statistically significant 
survival (Fig 2A).
Among 76 patients who had tissue NGS analysis, patients with BRAF alterations had 
significantly worse OS, and patients with lung metastases had better OS (statistically 
significant after the multivariable analysis). EGFR, MYC, and ERBB2 alterations in tissue 
DNA were not assessed because of the small number of patients harboring these alterations 
(fewer than 10 patients in each group; Data Supplement).
When survival was calculated from the time of blood draw (Table 2), the presence of 
nonsynonymous alterations in APC, BRAF, PIK3CA, EGFR, MYC, and ERBB2 genes as 
well as alterations with ctDNA of 5% or more were associated with a shorter median OS (all 
P < .05). However, only ERBB2 alterations remained significant in the multivariable model 
(Fig 2B).
Analysis of Outcomes for Patients With Matched Therapy Versus Patients With Unmatched 
Therapy
Outcomes of the patients who were treated with matched therapy after their ctDNA testing 
(n = 17) versus those who were given unmatched therapy (n = 18) were evaluated (Figure 
3A; Data Supplement). Patients had a median of one prior therapy in the metastatic setting. 
Overall, we observed improved outcomes for patients with matched therapy (Fig 3). 
Altogether, 65% of patients in the matched therapy group attained SD for 6 months or more, 
PR, or CR versus 31% of patients in the unmatched therapy group (P = .060 in univariable 
analysis; P = .045 in multivariable analysis [multivariable analysis was performed using line 
of therapy as a confounding variable]). In addition, patients in the matched therapy group 
had a median PFS of 6.1 months compared with 2.3 months for patients in the unmatched 
therapy group (P = .143 for univariable analysis; P = .079 for multivariable analysis). 
Finally, patients who received matched therapy survived longer than unmatched therapy 
group, with a median OS (calculated from the treatment start date) not reached (at 11.1 
months) compared to 9.4 months, respectively (albeit not statistically significant; Data 
Supplement).
Illustrative Case: Serial ctDNA Testing in a Patient Who Progressed While Receiving Anti-
EGFR–Based Therapy
A 49-year-old-man with metastatic rectal adenocarcinoma was started on fourth-line therapy 
with irinotecan plus cetuximab. The patient’s baseline ctDNA when therapy was initiated 
showed alterations including APC E422* (2.2%) and TP53 S127F (1.9%) (Fig 4A). Tumor 
regression was initially seen, but upon progression that included new lung metastases and 
lymphangitic spread (Fig 4B), ctDNA among previously observed alterations increased 
approximately 20-fold (33.8% for APC E422*; 39% for TP53 S127F), and emerging 
alterations included APC I1307fs and EGFR amplification (Fig 4A).
DISCUSSION
Despite the expansion of our recent understanding of the molecular biology of colorectal 
cancer6,7 and the development of salutary systemic therapies for advanced-stage disease, 
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overall prognosis remains poor.4,5 Thus, there is an urgent need for innovative treatment 
approaches for patients with metastatic colorectal cancer. Here we present the biologic 
features and clinical correlates of genomic alterations among 94 patients with mostly 
advanced-stage colorectal cancer by using targeted NGS that assessed ctDNA.
Overall, 79% of patients (74 of 94) had one or more nonsynonymous ctDNA alterations 
(Table 1). The most frequently characterized alterations were in TP53 (51% of patients) 
followed by KRAS (34%), APC (27%), BRAF (16%), PIK3CA (16%), and EGFR (15%) 
genes (Fig 1). Although the frequency of APC alterations detected in this study is less than 
what has been previously reported, frequencies of other genomic alterations are consistent 
with those in previous publications.21,22 Concordance was statistically significant between 
ctDNA and tissue DNA among the driver or truncal gene alterations (overall concordance: 
TP53, 68%; KRAS, 74%; APC, 63%; BRAF, 86% [all P < .05]). Hong et al29 previously 
reported that the ctDNA NGS had 100% sensitivity for tissue-detected as well as digital 
droplet polymerase chain reaction-based plasma-detected BRAFV600E mutation among 
patients with colorectal cancer, which is consistent with our data. Considering that 
BRAFV600E is targetable with a combination of anti-EGFR and anti-BRAF therapies, testing 
for this alteration is important.12 It should be noted that some of the high overall 
concordance was driven by negative concordance. Sensitivity of ctDNA was variable for 
detection of mutations found in tissue. For instance, sensitivity of ctDNA for detection of 
patients with tissue APC positivity was 44.9%; sensitivity of ctDNA for detection of those 
with tissue BRAF positivity was 80% (this analysis was not restricted to BRAFV600E). The 
apparent low capacity for detecting APC alterations could have implications for plasma 
monitoring of this alteration.
We did not observe differences in the concordance rate of driver alterations when we 
compared patients with a time interval between the blood draw and tissue biopsy of 6 
months or less versus more than 6 months (Data Supplement). This observation differs from 
previous reports, which showed that the longer the time interval between the two tests, the 
lower the rate of concordance.20,30 The small number of patients in each of our subgroups 
may have confounded our ability to discern such differences.
Importantly, certain clinical and ctDNA factors were associated with survival outcome. 
When survival was evaluated from the time of blood draw to the last follow-up, the presence 
of APC, BRAF, PIK3CA, EGFR, MYC, and ERBB2 nonsynonymous alterations (including 
single-nucleotide variations and amplifications) were all associated with poor overall 
survival (all P < .05 by univariable analysis), and ERBB2 alterations remained significant 
after the multivariable analysis (P < .001) (Table 2; Fig 2). Many of these poor prognostic 
alterations are potentially targetable with either FDA-approved drugs (on- or off-label use) 
or with investigational agents currently in clinical development. Examples include using an 
EGFR inhibitor (eg, cetuximab) plus a BRAF inhibitor (eg, vemurafenib) for patients with 
BRAF alterations12 and anti-HER2 agents (eg, trastuzumab and/or lapatinib) for ERBB2 
alterations.31
Accumulating evidence suggests that a biomarker-based approach to selecting targeted 
therapies, especially if they are based on genomic markers, is associated with improved 
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outcomes.32–36 Despite the relatively small numbers of patients in our study, we observed 
improvement in disease parameters in patients who received matched therapies (n = 17) 
compared with patients who received unmatched therapies (n = 18; SD was 6 months or 
more, PR, or CR [65% v 31%; P = .045]; median PFS, 6.1 v 2.3 months [P = .079]; median 
OS, not reached v 9.4 months [P = .146] using multivariable analysis; Figs 3–4; Data 
Supplement). The change in PFS and OS represented a nonsignificant trend, suggesting the 
need for larger studies. However, other factors may be operative and could have confounded 
our results. For instance, patients often received concomitant chemotherapy, and the putative 
interaction between TP53 and bevacizumab could have inflated the results.37–39 These 
considerations are important because some matched therapies have not proved to be effective 
in colorectal cancers.40,41
Although the precision medicine approach of matching patients with genomically or 
immunotargeted treatments is potentially promising, there are challenges for implementing 
this strategy (eg, tumor heterogeneity and genomic complexity among patients). In this 
study, we observed a median of three alterations per patient (range, zero to 30 alterations), 
and among 74 patients with one or more alterations, there were no two patients with 
identical molecular profiles. These findings suggest that matched monotherapy may not be 
optimal. Rather, customized combinations are most likely required for each individual. 
Preliminary results from the I-PREDICT (NCT02534675; Investigation of Profile-Related 
Evidence Determining Individualized Cancer Therapy) study of patients with aggressive 
malignancies showed a statistically significant improvement in time-to-treatment failure 
among patients receiving individualized combinations of matched therapies on the basis of 
genomic alterations when compared with patients receiving unmatched therapies.42 
Expansion of this trial is ongoing.
We have also observed that patients who had high mutation allele frequency (MAF) and 
ctDNA of 5% or more had significantly worse survival (Table 2), which is consistent with 
previous reports.20,30 This observation is not surprising because ctDNA levels are reflective 
of the underlying tumor burden and can undergo dynamic changes after therapy.43,44 
Moreover, Tie et al45 reported that, among patients with early-stage colon cancer who had 
surgical resection, detection of postsurgical ctDNA was strongly associated with recurrent 
disease, which indicates that ctDNA can be a very sensitive biomarker for residual disease 
and treatment response. Along with this notion, we have also presented a patient with 
metastatic rectal adenocarcinoma whose ctDNA level increased by 20-fold when his tumor 
showed progression of lung metastases and lymphangitic spread while he was receiving 
treatment with irinotecan and cetuximab (Fig 4). It is unclear at this time whether increases 
in ctDNA level warrant a change in treatment strategy. Similarly, it is uncertain whether 
addition of new targeted therapy agents upon progression is warranted. In this study, EGFR 
amplification surfaced along with tumor progression while the patient was receiving anti-
EGFR therapy (cetuximab; Fig 4). Emergence of alterations similar to those in ctDNA and 
other anomalies such as the appearance of KRAS alterations have been implicated in the 
evolution of resistance in patients with colorectal cancer who were treated with EGFR 
inhibitors.46
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There were several limitations to our study. First, it was performed retrospectively with a 
relatively small sample size at a single institution. Thus, our clinical findings require further 
validation with prospective studies. Second, multiple comparisons could result in 
overestimating the implications of P values; however, we have included a Bonferroni 
correction to attenuate this limitation. Third, it would be interesting to determine the impact 
of microsatellite stability status on the ctDNA alteration profile; this analysis could not be 
performed in this study because only 26 of our patients had microsatellite testing and 25 of 
them were microsatellite stable. Finally, because of the limited number of patients and the 
variable duration of time between tissue and ctDNA sampling, it was not feasible to analyze 
the effect of MAF for different alterations or the correlation between tissue and ctDNA 
MAF. Despite these limitations, our study provided an in-depth investigation of the clinical 
utility of ctDNA testing among patients with colorectal cancer.
In conclusion, we have interrogated tumors from 94 patients with mostly advanced-stage 
colorectal cancer who had clinical-grade NGS performed on blood-derived ctDNA. The 
median number of nonsynonymous alterations per patient was three and, importantly, each 
patient harbored a unique molecular profile. Concordance with common alterations in tissue 
ranged from 63% to 86%; differences between ctDNA and tissue could reflect dynamic 
changes in ctDNA after treatment. As was demonstrated by an illustrative patient, ctDNA 
may be shed from multiple metastatic sites or there could be differences in sensitivity 
between tissue and ctDNA sequencing. The presence of ctDNA of less than 5% 
independently correlated with longer survival, whereas ERBB2 ctDNA nonsynonymous 
alterations were associated with shorter survival. Although the number of patients receiving 
targeted therapy in our study was modest, this is the first study, to our knowledge, to 
demonstrate objective evidence of the clinical utility of ctDNA NGS in metastatic colorectal 
cancer across multiple biomarkers beyond BRAFV600E. Further clinical investigations using 
ctDNA to guide therapy in patients with colorectal cancer are needed.47
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Appendix
Methods
Digital sequencing of circulating tumor DNA.
Circulating tumor DNA (ctDNA sequencing was performed by Guardant Health, which was 
previously described (Guardant360, Redwood City, CA; http://www.guardanthealth.com/
guardant360/). Guardant360 is a clinical laboratory certified by the Clinical Laboratory 
Improvement Amendment, accredited by the College of American Pathologists, and 
approved by the New York State Department of Health. The analytical and clinical 
validation of Guardant360 was conducted in conformance with evidentiary standards 
established by the Standards for Reporting of Diagnostic Accuracy, Reporting of Tumor 
Marker Studies, Evaluation of Genomic Applications in Practice and Prevention, recent 
next-generation sequencing (NGS), and Standardization of Clinical Testing Biomarker 
Guidelines.16
The sequencing uses molecular barcoding and hybrid capture followed by NGS of the 
critical exons in a panel of 54 to 73 genes and reports all four major types of genomic 
alterations (point mutations, insertions-deletions [indels], fusions, and copy number 
amplifications)16,23 See the Data Supplement for detailed gene panels. The analytic 
sensitivity reaches detection levels of one to two single mutant fragments from a 10-mL 
blood sample (0.1% limit of detection), and analytic specificity is greater than 99.9999%. 
The fractional concentration or mutation allele frequency (MAF) for a given somatic 
mutation is calculated as the fraction of ctDNA harboring that mutation in a background of 
wild-type ctDNA fragments at the same nucleotide position. The lower limit of detection of 
ctDNA was 0.04% for single nucleotide variants and fusions and 0.02% for indels.16,24 Only 
nonsynonymous alterations that include characterized alterations and variants of unknown 
significance (VUSs) were included in our analysis. When characterized alterations are 
referred to, VUSs were excluded in the analysis.
NGS of tissue.
Overall, 76 (81%) of 94 patients who had ctDNA results also had NGS performed by 
agencies accredited by Clinical Laboratory Improvement Amendment and the College of 
American Pathologists on tumor tissue using the FoundationOne assay (http://
www.foundationone.com/; hybrid capture–based NGS; 182, 236, or 315 genes, depending 
on the time period). At > 250× median depth of coverage, > 99% of base substitutions 
present at MAF ≥ 10% were successfully detected. For indels at MAF ≥ 20%, 98% were 
detected. The methods have been previously described.25
Concordance Rate
For the 76 patients who had both types of tests (tissue NGS and plasma ctDNA testing that 
covered the same genes and alteration types revealed in the tissue NGS), we assessed the 
concordance for the most frequent alterations and the corresponding kappa statistic, which is 
a conservative measurement of relative agreement that takes into account agreement by 
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chance. Kappa values range from 1 (perfect agreement) to 0 (no agreement other than what 
would be expected by chance).26
Matched Therapy and Actionability
We retrospectively analyzed the treatments given after ctDNA testing and compared the 
clinical outcomes among patients who received matched and unmatched therapies. A 
therapy was considered matched if at least one agent in the treatment regimen targeted at 
least one abnormality or pathway component aberrant in a patient’s ctDNA molecular 
profile. Patients were evaluable if therapy was administered for more than 10 days.
Actionability implies that the protein product of a genomic abnormality can be affected by a 
specific targeted drug.27 A potentially actionable alteration was defined as an alteration that 
was either the direct target (such as an EGFR inhibitor targeting an EGFR mutation) or a 
pathway component (such as an mTOR inhibitor for a PIK3CA mutation [because mTOR is 
downstream of PIK3CA]) that could be targeted by at least one US Food and Drug (FDA)–
approved or investigational drug in a clinical trial. Actionability was considered at the 
variant level; VUSs (functional consequences and clinical significance of these gene variants 
are not established, as opposed to characterized alterations) were considered nonactionable.
Statistical Analysis
Medians and 95% CIs or ranges were reported. Fisher’s exact tests were used to compare 
categorical variables, and the nonparametric Mann-Whitney U test was used to compare two 
groups on one continuous variable. Binary logistic regressions were performed for 
categorical end points, and multiple linear regressions were performed for continuous 
variables. The rate of stable disease of 6 months or more, partial response, or complete 
response was compared between patients with matched and unmatched therapy. Stable 
disease, partial response, or complete response was determined per assessment of the 
treating physician. Progression-free survival was defined as the time from the beginning of 
therapy to progression or last follow-up date for patients who did not progress. Overall 
survival was defined as the time from diagnosis until death or last follow-up date for patients 
still alive. Progression-free survival and overall survival were analyzed by the Kaplan-Meier 
method,28 and the log-rank test (univariable analysis) or Cox regression model 
(multivariable analysis) was used to compare variables. When appropriate, Bonferroni 
correction was used for multiple comparisons. Statistical analysis was performed by M.C.S. 
with SPSS version 24.0 (SPSS, Chicago, IL).
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Fig A1. 
Concordance between circulating tumor DNA (ctDNA) and tissue DNA analyses among 
commonly altered genomic alterations. NGS, next-generation sequencing.
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Fig 1. 
(A) Pie chart showing the types of alterations in the overall population (N = 94). In total, 375 
nonsynonymous alterations were detected in 94 patients (74 patients had at least one 
alteration). Other alterations included three deletions, three insertions, and one fusion.. 
Frequencies are percent of alterations. (B) Frequency of the most common circulating tumor 
DNA (ctDNA) alterations. Only genes that were altered in five or more patients are 
displayed in the bar graph. The other altered genes in our population (fewer than five 
patients had the alteration) were ABL1, AKT1, ALK, ARAF, ATM, BRCA1, CCND1, 
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CCND2, CCNE1, CDH1, CDK6, CDKN2A, CTNNB1, ESR1, FGFR3, GNAQ, GNAS, 
HRAS, JAK3, KIT, MAP2K1, MLH1, MTOR, NOTCH1, NRAS, PTEN, RAF1, RB1, RET, 
RHOA, RIT1, ROS1, SDK6, SMO, STK11, VHL. This analysis included only 
nonsynonymous alterations. Alterations of unknown significance (variant of unknown 
significance; VUSs) versus characterized mutations (indels, amplifications, fusions, and 
single nucleotide variant (SNV) point mutations) were considered at the variant level. 
Multiple alteration indicates that different alterations were found in same gene (eg, 
alterations in both BRAF amplification and SNVs found in same patient). Frequencies are 
percent of patients. (C) Oncoprint of the most frequent alterations. Only alterations 
identified in more than 10 patients were represented. Each row represents the mentioned 
alteration; each column represents one patient. Only patients with at least one alteration in 
one of these genes—TP53, KRAS, APC, BRAF, PIK3CA, EGFR, MYC, or ERBB2—are 
displayed (n = 71 patients; the other 23 patients had no alterations in the represented genes 
and their corresponding columns would have been empty or white). (D) Pie charts 
representing the potential actionability of the detected alterations in the overall population 
(N = 94; left) and in patients with at least one nonsynonymous alteration (n = 74; right). 
Percentages are percent of patients. FDA, US Food and Drug Administration.
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Fig 2. 
Kaplan-Meier curves for overall survival analysis from (A) the time of diagnosis and (B) the 
time of blood draw used for the ctDNA testing. The variables that were significant in the 
multivariable analyses (Table 2) are represented. P values are from the log-rank test.
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Fig 3. 
Treatment outcome analyses. (A) Diagram representing the treatment analyses and 
comparison of patients with matched treatment v patients with unmatched treatment. (B) 
Kaplan-Meier curves comparing the progression-free survival (PFS) for the patients with 
matched treatment (n = 17) v patients with unmatched treatment (n = 18). Univariable 
analysis (log-rank test) P = .143; multivariable analysis (Cox regression) P = .079. (C) 
Comparison of response outcomes for evaluable patients with matched treatment (n = 17) v 
those with unmatched treatment (n = 16). Univariable analysis (logistic regression) P = .060; 
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multivariable analysis (multiple logistic regression) P = .045. CR, complete response; 
ctDNA, circulating tumor DNA; PD, progressive disease; PR, partial response; SD, stable 
disease.
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Fig 4. 
Patients who had serial circulating tumor DNA (ctDNA) testing and were progressing on 
anti-EGFR–based therapy. A 49-year-old-man with metastatic adenocarcinoma of the 
rectum had a history of previous treatment with (1) capecitabine plus oxaliplatin and (2) 
fluorouracil plus irinotecan plus bevacizumab; (3) treatment on a clinical trial with anti-
CD73 included fourth-line therapy with irinotecan plus cetuximab. (A) Patient’s baseline 
ctDNA at the start of therapy showing alterations (amount in percent). (B) The patient 
showed initial tumor regression, but at 9 months, the tumor progressed with new lung 
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metastases and lymphangitic spread (red arrow). ctDNA among previously observed 
alterations increased approximately 20-fold (33.8% for APC E422*; 39% for TP53 S127F) 
along with emerging alterations, including MTOR E162V, APC I1307fs, and EGFR 
amplification. Among the ctDNA alterations observed in this patient, the following were 
characterized alterations: TP53 S127F, APC E422*, APC I1307fs, and EGFR amplification. 
MTOR E162V was a variant of uncertain significance; ARID1A K1808K was a 
synonymous substitution. (†) Only levels of ctDNA mutations were quantified using 
%ctDNA and represented; EGFR amplification was detected at progression but not 
quantified.
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r c
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 c
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ra
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a
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N
OT
E.
 T
hi
s t
ab
le
 in
cl
ud
es
 o
nl
y 
th
os
e 
va
ria
bl
es
 w
ith
 a
t l
ea
st 
10
 p
at
ie
nt
s h
av
in
g 
th
e 
de
sig
na
te
d 
ch
ar
ac
te
ris
tic
. I
n 
so
m
e 
in
sta
nc
es
, t
he
 st
an
da
rd
 e
rro
r c
ou
ld
 n
ot
 b
e 
co
m
pu
te
d 
(—
). O
nly
 va
ria
bl
es
 th
at
 w
er
e 
sig
ni
fic
an
t i
n 
th
e 
un
iv
ar
ia
bl
e 
m
od
el
s (
log
-ra
nk
 te
st)
 w
ere
 in
clu
de
d i
n t
he
 m
ult
iva
ria
bl
e 
an
al
ys
is 
(C
ox
 re
gr
es
sio
n 
m
od
el
), w
ith
 th
e f
in
al
 m
od
el
 c
on
ta
in
in
g 
on
ly
 si
gn
ifi
ca
nt
 c
ov
ar
ia
bl
es
 in
 th
e 
m
ul
tiv
ar
ia
bl
e 
an
al
ys
es
 (f
orw
ar
d 
ste
pw
ise
 se
le
ct
io
n 
m
od
el
). A
ll o
f t
he
 al
ter
ati
on
s l
ist
ed
 ar
e n
on
sy
no
ny
m
ou
s (
va
ria
nt
s o
f u
nk
no
w
n
 s
ig
ni
fic
an
ce
 [V
US
s] 
are
 in
clu
de
d).
 T
he
 W
al
d 
sta
tis
tic
 te
sts
 th
e 
un
iq
ue
 c
on
tri
bu
tio
n 
of
 e
ac
h 
v
ar
ia
bl
e;
 th
e 
hi
gh
er
 th
e 
W
al
d 
sta
tis
tic
, t
he
 h
ig
he
r t
he
 a
ss
oc
ia
tio
n 
or
 c
on
tri
bu
tio
n 
in
 th
e 
m
od
el
.
A
bb
re
v
ia
tio
ns
: c
tD
N
A
, c
irc
ul
at
in
g 
tu
m
or
 D
N
A
; N
R,
 n
ot
 re
ac
he
d.
*
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ly
 a
lte
ra
tio
ns
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cl
ud
ed
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 th
e 
m
ul
tiv
ar
ia
bl
e 
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al
ys
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F 
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=
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4) 
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B2
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=
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4) 
rem
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 si
gn
ifi
ca
nt
ly
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oc
ia
te
d 
w
ith
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or
te
r s
ur
vi
v
al
. F
o
r 
an
al
ys
is 
of
 c
tD
N
A
 o
f 5
%
 o
r m
or
e, 
al
l 
n
o
n
sy
no
ny
m
ou
s a
lte
ra
tio
ns
 w
er
e 
in
cl
ud
ed
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he
n 
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am
in
in
g 
th
e 
de
ta
ile
d 
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lts
, a
ll 
bu
t o
ne
 p
at
ie
nt
 h
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 o
ne
 o
r m
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ar
ac
te
riz
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lte
ra
tio
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ith
 c
tD
NA
 o
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%
 o
r m
or
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in 
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t, t
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ati
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D
N
A
 o
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%
 o
r m
or
e w
as
 c
la
ss
ifi
ed
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s a
 V
U
S 
[R
O
S1
 D
17
76
H
; 3
5.
23
%
]).
† B
on
fe
rro
ni
-c
or
re
ct
ed
 P
 
v
al
ue
 le
v
el
 o
f s
ig
ni
fic
an
ce
 w
as
 .
00
7 
(co
rre
cte
d f
or 
mu
ltip
le 
co
mp
ari
so
ns
). O
nly
 th
e v
ar
ia
bl
es
 w
ith
 P
 
<
 .0
07
 w
er
e 
co
ns
id
er
ed
 si
gn
ifi
ca
nt
.
‡ In
 m
ul
tiv
ar
ia
bl
e 
an
al
ys
is,
 lu
ng
 m
et
as
ta
se
s c
or
re
la
te
d 
w
ith
 lo
ng
er
 su
rv
iv
al
.
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